[go: up one dir, main page]

WO2015012174A1 - 細胞濃縮液の製造方法および細胞懸濁液処理システム - Google Patents

細胞濃縮液の製造方法および細胞懸濁液処理システム Download PDF

Info

Publication number
WO2015012174A1
WO2015012174A1 PCT/JP2014/068936 JP2014068936W WO2015012174A1 WO 2015012174 A1 WO2015012174 A1 WO 2015012174A1 JP 2014068936 W JP2014068936 W JP 2014068936W WO 2015012174 A1 WO2015012174 A1 WO 2015012174A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell suspension
storage container
cell
circulation
concentrate
Prior art date
Application number
PCT/JP2014/068936
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
修平 谷口
伸好 梅田
敬章 坂下
宙 櫻井
Original Assignee
株式会社カネカ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社カネカ filed Critical 株式会社カネカ
Priority to US14/906,320 priority Critical patent/US10113144B2/en
Priority to CN201480041539.XA priority patent/CN105408467A/zh
Priority to EP14829330.1A priority patent/EP3026107B1/de
Publication of WO2015012174A1 publication Critical patent/WO2015012174A1/ja
Priority to US16/142,857 priority patent/US10533151B2/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/46—Means for regulation, monitoring, measurement or control, e.g. flow regulation of cellular or enzymatic activity or functionality, e.g. cell viability
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0209—Multiple bag systems for separating or storing blood components
    • A61M1/0218—Multiple bag systems for separating or storing blood components with filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0281—Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3403—Regulation parameters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3403—Regulation parameters
    • A61M1/3406—Physical characteristics of the filtrate, e.g. urea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3601—Extra-corporeal circuits in which the blood fluid passes more than once through the treatment unit
    • A61M1/3603—Extra-corporeal circuits in which the blood fluid passes more than once through the treatment unit in the same direction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3643—Priming, rinsing before or after use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3643—Priming, rinsing before or after use
    • A61M1/3644—Mode of operation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3692—Washing or rinsing blood or blood constituents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M27/00—Means for mixing, agitating or circulating fluids in the vessel
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M33/00—Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus
    • C12M33/04—Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus by injection or suction, e.g. using pipettes, syringes, needles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/44—Means for regulation, monitoring, measurement or control, e.g. flow regulation of volume or liquid level
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/48—Automatic or computerized control
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3626—Gas bubble detectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3379—Masses, volumes, levels of fluids in reservoirs, flow rates
    • A61M2205/3389—Continuous level detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3379—Masses, volumes, levels of fluids in reservoirs, flow rates
    • A61M2205/3393—Masses, volumes, levels of fluids in reservoirs, flow rates by weighing the reservoir

Definitions

  • the present invention relates to a technique for concentrating a cell suspension using a cell suspension treatment system having a cell suspension treatment device filled with a hollow fiber separation membrane.
  • cells used for treatment when cells used for treatment are administered to a patient, they may be immediately collected after being collected from a living body, or may be administered to a patient again after being cultured in vitro.
  • the cells used for these treatments are generally transplanted after undergoing a cell preparation process such as washing with a suspension suitable for treatment and concentrating to a liquid volume suitable for administration. Washing means replacing a body fluid or a medium in which cells are suspended with a physiological saline solution or an infusion solution.
  • a washing process in which dilution and concentration are repeatedly performed on the cell concentrate, unnecessary impurities in the cell concentrate can be removed, and the cell concentrate can be suitably used for transplantation to humans and animals.
  • a cell preparation method for example, concentration and washing operations using centrifugation are known.
  • the cell suspension is stored in a sealed container and the cells are precipitated by centrifugation for concentration washing of the cells. Then, with a clean bench, open the container and remove the suspension supernatant. At this time, the cells are released to the atmosphere, and there is a concern about the possibility of quality deterioration such as contamination. Therefore, although a centrifugal operation in a closed system has been proposed (Patent Document 1), there is a concern that the apparatus becomes large and the cost increases.
  • Patent Document 2 As another cell preparation method, a method for concentrating and washing a cell suspension using a rotating membrane filter has been proposed (Patent Document 2). According to this method, the apparatus can be made compact and simple, and cells can be handled aseptically in a closed circuit.
  • Patent Document 2 in order to automatically advance the concentration cleaning process, the weight of the storage container is measured by a weight scale, and the process is automatically advanced by feeding back the weight change to the process control. As a means.
  • there are concerns about accuracy and responsiveness due to changes in weight and there is a concern that switching between processes will be performed accurately. Concentration and washing of cell suspensions may not be performed accurately, and there may be defects in quality. There is.
  • Patent Document 3 a system for filtering and washing using a filtering means has been proposed.
  • This system is a system for the purpose of reusing patient blood lost due to surgery or the like.
  • the amount of blood stored in the storage tank is kept within a certain range while using the blood level sensor for the blood stored in the storage tank.
  • a bubble detector detects bubbles in the system and controls the process. By performing control by detecting such bubbles, the amount of liquid in the circuit can be grasped accurately and quickly, so that switching of each process can be expected to be performed accurately and immediately.
  • the above-mentioned system is a system for blood, and mixing of bubbles in blood processing is harmful.
  • a system for detecting bubbles is used to remove unnecessary components that are the purpose of the cell preparation process, It is not supposed to be applied to a concentration system in order to reduce the amount of liquid to be administered.
  • hollow fibers are used as in the above patent.
  • the mixing of bubbles may adversely affect the separation performance of the hollow fiber. There is concern about the effect on the cleaning efficiency.
  • An object of the present invention is to solve the above-mentioned problems in the production of a cell concentrate using a hollow fiber separation membrane, with a low risk of cell loss and contamination, low damage to cells, and a cell concentrate.
  • the object is to provide a method of manufacturing with high accuracy.
  • Another object of the present invention is to provide a cell suspension treatment system capable of efficiently producing the cell concentrate as described above.
  • the inventors of the present invention have a cell suspension treatment device filled with a hollow fiber separation membrane, a container for storing cells, the inside of this storage container, or a storage container and a cell. Equipped with a device that detects the amount of liquid in the tube that communicates with the suspension treatment device, and a circuit that connects the cell suspension so that it can be concentrated while circulating the cell suspension.
  • a device that detects the amount of liquid in the tube that communicates with the suspension treatment device and a circuit that connects the cell suspension so that it can be concentrated while circulating the cell suspension.
  • the present invention provides the following. (1) a cell suspension reservoir having a solution inlet port, a circulation outlet port and a circulation inlet port; Cell suspension treatment for filtering and concentrating a liquid from a cell suspension, in which a hollow fiber separation membrane is filled in a container having a cell suspension inlet, a cell suspension outlet and a filtrate outlet And Circulation inlet port for communicating the circulation inlet port of the storage container and the cell suspension inlet of the cell suspension treatment device, and the cell suspension outlet of the cell suspension treatment device and the circulation of the storage container A circulation circuit for performing concentration while circulating the cell suspension between the storage container and the cell suspension treatment device, comprising a lead-out communication pipe communicating with the outlet port; A collection container for the concentrated cell concentrate; A collection path for sending the cell concentrate in the storage container, the cell suspension treatment device and the circulation circuit to the collection container; An injection path for injecting the solution into the solution inlet port of the storage container; A method for producing a cell concentrate using a cell suspension treatment system comprising a detecting means for detecting
  • Concentrating the suspension c) a step of stopping the step b) by detecting the amount of the cell concentrate in the storage container or the communication pipe for introduction of the circulation circuit; d) A method for producing a cell concentrate, comprising a step of sending the cell concentrate in the storage container, the cell suspension treatment device, and the circulation circuit to the recovery container through a recovery path and recovering the cell concentrate.
  • the cell concentration is repeated by further repeating the steps b) and c) Liquid manufacturing method.
  • the method for producing the cell concentrate wherein priming is performed by injecting a priming solution from the solution inlet port before the step a).
  • the manufacturing method of the said cell concentrate which implements a process and b process in parallel.
  • the method for producing the cell concentrate wherein the detection means for detecting the amount of liquid in the circulation circuit is a bubble sensor provided in the communication pipe for introduction of the circulation circuit.
  • the manufacturing method of the said cell concentrate which is a bubble sensor with which the detection means which detects the liquid quantity in a storage container is equipped with one or more on the circuit parallel to a storage container and communicating with the lower part of a storage container.
  • the manufacturing method of the said cell concentrate which has the chamber in the circuit connected with the said storage container lower part.
  • a cell suspension reservoir having a solution inlet port, a circulation outlet port and a circulation inlet port;
  • a cell suspension for filtering and concentrating a liquid from a cell suspension in which a hollow fiber separation membrane is filled in a container having a cell suspension inlet, a cell suspension outlet and a filtrate outlet
  • a processor Circulation inlet port for communicating the circulation inlet port of the storage container and the cell suspension inlet of the cell suspension treatment device, and the cell suspension outlet of the cell suspension treatment device and the circulation of the storage container
  • An injection path for injecting the solution into the solution inlet port of the storage container;
  • Detecting means for detecting the amount of the cell concentrate in the storage container or in the communication pipe for
  • the cell suspension treatment system wherein the detection means for detecting the amount of liquid in the circulation circuit is a bubble sensor provided in the communication pipe for introduction of the circulation circuit.
  • the cell suspension processing system wherein the detection means for detecting the amount of liquid in the storage container is a bubble sensor provided on a circuit parallel to the storage container and communicating with the lower part of the storage container.
  • the cell suspension treatment system comprising a chamber in a circuit communicating with the lower part of the storage container.
  • the cell suspension processing system wherein a bubble sensor is provided in the injection path.
  • the cell suspension treatment system wherein the solution inlet port, the circulation outlet port, and the circulation inlet port are all provided in a lower part of the storage container.
  • the cell suspension treatment system comprising a vent near the top of the storage container, and the storage container is open to the atmosphere.
  • the cell concentrate was concentrated to a predetermined amount by the detecting means.
  • the cell concentrate is sent from the storage container to the cell suspension processor, and the cell concentrate is aseptically removed with low cell damage and low risk of cell loss and contamination.
  • the diluent is injected into the storage container to dilute the cell concentrate in the storage container, and then the b) concentration step and c) the concentration stop step are further repeated.
  • unnecessary components in the cell concentrate can be removed, and a cell concentrate with higher purity can be obtained.
  • a) priming solution is injected from the solution inlet port before the storing step, and priming is performed, so that cell concentration can be performed with good workability.
  • the processing time can be shortened by performing the a) storage step and b) the concentration step in parallel.
  • the detection means for detecting the amount of liquid in the circulation circuit of the cell suspension treatment system is a bubble sensor provided in the communication pipe for introduction of the circulation circuit, so that the amount of liquid in the storage container is reduced. Since the cell suspension can be concentrated more than in the case of detection, the amount of the concentrated suspension can be reduced, and the amount of unnecessary components in the suspension can be reduced.
  • the detection means for detecting the amount of liquid in the storage container is a bubble sensor provided at least on a circuit parallel to the storage container and communicating with the lower part of the storage container.
  • the range for detecting the liquid level in the circuit may be narrow, and a compact bubble sensor can be used.
  • the chamber is provided in the circuit communicating with the lower part of the storage container, it is possible to reduce the occurrence of problems detected by the bubble sensor even if bubbles are intruded into the circuit by mistake.
  • the bubble sensor is provided in the injection path, even if the processing amount of the target cell suspension is not known in advance, the bubbles that have entered the injection path after the cell suspension has disappeared are removed. Since the sensor detects, the entire amount of the target liquid can be processed without setting the pump drive time for each process.
  • the solution inlet port, the circulation outlet port, and the circulation inlet port are all provided in the lower part of the storage container, the cell suspension and the solution for dilution supplied to the storage container through the solution inlet port Can be efficiently mixed and agitated with the liquid circulating in the storage container and the circulation circuit, allowing efficient concentration and dilution.
  • vents are provided near the upper part of the storage container, and the storage container collapses when the container is decompressed to discharge the liquid in the storage container because the storage container is open to the atmosphere. Can be prevented.
  • the method for producing the cell concentrate of the present invention comprises: A cell suspension reservoir having a solution inlet port, a circulation outlet port and a circulation inlet port; Cell suspension treatment for filtering and concentrating a liquid from a cell suspension, in which a hollow fiber separation membrane is filled in a container having a cell suspension inlet, a cell suspension outlet and a filtrate outlet And Circulation inlet port for communicating the circulation inlet port of the storage container and the cell suspension inlet of the cell suspension treatment device, and the cell suspension outlet of the cell suspension treatment device and the circulation of the storage container A circulation circuit for performing concentration while circulating the cell suspension between the storage container and the cell suspension treatment device, comprising a lead-out communication pipe communicating with the outlet port; A collection container for the concentrated cell concentrate; A collection path for sending the cell concentrate in the storage container, the cell suspension treatment device and the circulation circuit to the collection container; An injection path for injecting the solution into the solution inlet port of the storage container; A cell suspension processing system is used that includes a detection means for detecting the amount of the cell concentrate in
  • the storage container used in the cell suspension processing system stores a cell suspension for processing, and receives a cell concentrate obtained by passing the cell suspension through a cell suspension processor as described later.
  • the storage container has a solution inlet port, a circulation outlet port, and a circulation inlet port.
  • the solution inlet port refers to a port for supplying the cell suspension into the storage container.
  • the circulation inlet port refers to a port for passing the liquid from the storage container to the cell suspension treatment device, and the circulation outlet port refers to the flow of the cell concentrate concentrated by the cell suspension treatment device through the storage container.
  • the cell suspension supplied through the solution inlet port and the solution for dilution are efficiently agitated with the liquid circulating in the storage container and the circulation circuit.
  • the number of solution inlet ports, circulation outlet ports, and circulation inlet ports may be one each, but may be increased to a plurality as necessary.
  • the solution inlet port can be used not only as a cell suspension but also as a port for a diluting solution or a priming solution.
  • an inlet port for a diluting solution or a priming solution May be provided.
  • a target port different from the above three types of ports may be provided.
  • a collection port for passing the cell concentrate through the collection container can be mentioned.
  • the material of the storage container may be any material that does not affect the cells in the cell suspension or cell concentrate, but is preferably a flexible plastic from the viewpoint of good handling. Further, it is advantageous that the inner surface of the storage container is pear-finished because the remaining liquid can be reduced when the suspension is discharged from the storage container.
  • the volume of the storage container can be used without any particular limitation. However, if it is too large, a large amount of diluent used for dilution is required, and therefore it is preferably 1000 mL or less.
  • the shape of the storage container, the structure of each port, the material, etc. may be appropriately determined depending on the type and volume of the cell suspension to be treated, and there is no particular limitation.
  • a ventilation hole may be provided in the upper part of the storage container.
  • the atmosphere in the storage container can be exchanged with the atmosphere and the atmosphere can be exchanged. For example, when the liquid in the storage container is discharged, the storage container is decompressed and the storage container is crushed. There is an advantage to prevent.
  • This vent may be provided with an air filter, which can prevent unnecessary components from being mixed into the storage container from the outside.
  • the cell suspension treatment device is a device for filtering and concentrating liquid from the cell suspension, and is connected so that the cell suspension can be passed from the storage container.
  • a hollow fiber separation membrane is filled in a container having a cell suspension inlet, a cell suspension outlet, and a filtrate outlet.
  • the cell suspension introduction port is an inlet for introducing the cell suspension from the storage container into the cell suspension processor, and is connected to a circulation inlet port of the storage container.
  • the cell suspension outlet is an outlet for taking out the concentrated cell suspension (cell concentrate).
  • the cell suspension outlet is connected to the circulation outlet port of the storage container, whereby concentration is performed by circulating the cell suspension between the storage container and the cell suspension treatment device. Can do.
  • the filtrate outlet is an outlet for removing the filtered liquid from the cell suspension.
  • the hollow fiber separation membrane used in the cell suspension treatment apparatus preferably has a cylindrical container filled with several tens to thousands of hollow fibers bundled.
  • the arrangement of the hollow fiber separation membrane may be linear, bent, or spiral, and the hollow fiber is provided between the cell suspension inlet and the cell suspension outlet.
  • the shape is not particularly limited as long as both ends of the separation membrane are held.
  • a synthetic polymer material can be used for the hollow fiber separation membrane used in the cell suspension treatment device from the viewpoint of the safety and stability of the material.
  • polysulfone-based, polyolefin-based, or cellulose-based polymer materials can be preferably used.
  • the pore diameter of the hollow fiber separation membrane is not limited as long as cells do not leak to the outside, and is preferably as large as possible so that unnecessary components can be efficiently filtered. Specifically, those having an average pore diameter of 0.01 ⁇ m or more and 1.0 ⁇ m or less can be suitably used.
  • a hollow fiber having an inner diameter of 400 ⁇ m or more and 1000 ⁇ m or less is preferably used.
  • the liquid is filtered to the outside of the hollow fiber separation membrane to produce a cell concentrate.
  • a hollow container is filled with a hollow fiber separation membrane, and the end of the hollow fiber is in close contact with the end of the tubular container with an adhesive or the like, and is opened at the end.
  • a header portion serving as a cell suspension inlet or a cell suspension outlet is provided at the end of the cylindrical container so that the cell suspension can flow into and out of the hollow fiber membrane.
  • the cylindrical container only needs to have one or more outlets for filtrate, and the filtrate filtered from the inside of the hollow fiber is discharged from the outlet for filtrate.
  • the cell suspension treatment device needs to have a structure in which a hollow fiber separation membrane is filled in a sealed container, but the cell suspension inlet and the cell suspension outlet are connected to the hollow fiber from the filtrate outlet.
  • Various structures can be employed as long as the structure is separated by wall materials constituting the separation membrane.
  • a dialyzer used for hemodialysis can be exemplified as a similar structure.
  • a circuit for flowing out the filtrate separated by the hollow fiber separation membrane is installed at the outlet for the filtrate of the cell suspension treatment device. It is preferable to connect the circuit for the filtrate and the waste liquid container because the concern that the filtrate leaks to the outside can be reduced.
  • the filtrate taken out from the outlet for filtrate can be collected by passing it through a waste liquid container or the like.
  • the waste liquid container can be used without particular limitation as long as it does not leak waste liquid.
  • a pump for feeding the filtrate may or may not be installed between the filtrate outlet of the cell suspension treatment device and the waste container.
  • the filtrate can be discharged at a constant flow rate, so that the treatment time can be made constant and the filtration efficiency in the cell suspension treatment device can be increased. It becomes possible to control. That is, by driving the pump, the discharge of the filtrate from the cell suspension treatment device is promoted, and as a result, the concentration treatment in the cell suspension treatment device can be promoted.
  • rapid recovery can be achieved by stopping the pump.
  • the collected filtrate may be discarded as it is, or may be reused as a diluted solution of the cell culture solution by performing reprocessing such as sterilization.
  • the cell suspension processor sends the cell concentrate in the cell suspension processor to a collection container.
  • a cell concentrate recovery port may be provided.
  • the cell concentrate recovery port may be connected to the recovery container.
  • the circulation circuit includes a communication pipe for introduction that communicates a circulation inlet port of the storage container and a cell suspension inlet of the cell suspension processor, a cell suspension outlet of the cell suspension processor, It is a circuit comprising a lead-out communicating pipe that communicates with the circulation outlet port of the storage container.
  • a cell concentrate can be prepared by performing concentration through the circulation circuit while circulating the cell suspension between the storage container and the cell suspension treatment device.
  • a tube constituting the circulation circuit a general plastic tube can be suitably used. Vinyl chloride can be suitably used in terms of safety and durability.
  • a pump is installed in the circulation circuit from the viewpoint of facilitating the control of the circulation of the cell suspension or the cell concentrate.
  • the number of pumps there is no particular limitation on the number of pumps, but one is sufficient from the viewpoint of easy control.
  • the position of the pump it may be installed in either the introduction communication pipe or the extraction communication pipe, but if it is installed in the introduction communication pipe, the cell suspension introduction port of the cell suspension treatment device It is preferable that a solution having a high pressure can be introduced into the liquid and that the liquid can be efficiently separated.
  • a branch portion may be provided anywhere on the circulation circuit.
  • the path from the branch part to the recovery container is used as a final recovery path, in the storage container, in the cell suspension treatment device, and in the circulation.
  • the cell concentrate in the circuit can be quickly collected in the collection container.
  • the branching section be installed at a position as close as possible to the circulation outlet port because the amount of residual liquid remaining in the circulation circuit from the branching section to the outlet port can be reduced in the recovery step.
  • the collection container is a container for collecting a cell concentrate concentrated to a predetermined concentration.
  • the collection container may be a flexible plastic container. Moreover, if pear processing is given to the inner surface, there exists an advantage which can reduce the residual liquid after collect
  • the shape of the collection container is not particularly limited. For example, when the volume increases, the inner area of the container with which the collected cells come into contact increases, and the attached cells may remain in the container and lead to the loss of cells. .
  • the collection path is a path for sending the cell concentrate in the storage container, the cell suspension treatment device, and the circulation circuit to the collection container.
  • a general plastic tube can be used as the pipe constituting the recovery path, and among them, a vinyl chloride tube can be preferably used from the viewpoint of safety and durability.
  • Examples of the recovery path include the following three aspects. 1) When a branch portion is provided on the circulation circuit, a path connecting the branch portion and the recovery container is a recovery path. 2) When the recovery port of the storage container and the recovery container are connected, the connected path becomes the recovery path. 3) When the cell concentrate recovery port of the cell suspension treatment device and the recovery container are connected, this connected path becomes the recovery path.
  • the recovery path may be any of the above embodiments, but two or more may be used in combination.
  • the injection path is a path for injecting the solution into the solution inlet port of the storage container.
  • a general plastic tube can be used as the pipe constituting the injection path, and among them, a vinyl chloride tube can be preferably used from the viewpoint of safety and durability.
  • the solution referred to in the present invention includes a diluent for re-diluting a cell concentrate obtained by concentrating the cell suspension and a cell suspension treatment system before the concentration treatment.
  • a priming solution for priming the whole is included.
  • the diluent used in the present invention include physiological saline, infusion solution, distilled water, buffer solution, medium, plasma, inorganic salts, saccharides, serum, liquid containing protein, and the like from the viewpoint of safety.
  • An infusion solution can be suitably used.
  • the priming solution include physiological saline, infusion solution, distilled water, buffer solution, culture medium, plasma, inorganic salts, saccharides, serum, and liquids containing protein.
  • the same solution may be used as the diluting solution and the priming solution, or different solutions may be used.
  • a different solution it is possible to install a circuit that is separated from the branch portion on the circuit connected to the solution inlet port of the storage container and connected to each connection portion.
  • the other end of the injection path connected to the solution inlet port of the storage container is a connection for a cell culture bag, a diluent bag, or a priming solution bag.
  • a bottle needle, male luer, female luer, lock connection or the like can be used without particular limitation as long as it can be connected to a bag used for cell culture.
  • a bottle needle, male luer, female luer, lock connection, etc. can be used for the diluting solution bag connecting portion or the priming solution bag connecting portion without particular limitation as long as it can be connected to the bag in which the diluting solution or priming solution is stored.
  • a pump for feeding a liquid is installed in the injection path.
  • the pump can stably feed liquid to the storage container. Further, the position where the pump is installed is on the circuit connecting the junction point of the circuit connected to the cell culture bag connecting part, the diluent bag connecting part and the priming liquid bag connecting part and the solution inlet port. It is preferable from the point that the number of pumps required for the operation can be reduced.
  • the detection means is means for detecting the amount of the cell concentrate in the storage container or the communication pipe for introduction of the circulation circuit.
  • Examples of the means for detecting the liquid amount in the storage container include using a bubble sensor that directly detects the liquid level of the storage liquid in the storage container.
  • a tube is installed so as to be parallel to the vertical direction with respect to the storage container, and a circuit in which the storage container and the tube communicate with each other is formed below, and the liquid level in the tube is in the storage container.
  • the bubble sensor may be installed in this tube by adjusting it so that it is equal to the liquid level.
  • the liquid level in the tube can be detected by the bubble sensor as the liquid level in the storage container.
  • you may install a chamber under the said tube installed in parallel with the storage container. In particular, by installing a chamber having an inner diameter larger than that of the tube, it is expected to reduce the occurrence of defects that are detected by the intrusion of bubbles in the tubes installed in parallel.
  • a bubble sensor may be provided in the introduction communication tube communicating with the circulation inlet port of the storage container. If it is this form, since the cell suspension can be concentrated more than the means for detecting the amount of liquid in the storage container, the amount of the concentrated suspension (cell concentrate) can be reduced, There is an advantage that the amount of unnecessary components in the suspension can be reduced. Further, the position of the bubble sensor to be installed in the introduction communication pipe is not particularly limited, but by installing it at a position close to the storage container, the length of the circuit connecting the storage container and the bubble sensor can be increased. Can be shortened.
  • a bubble sensor may be installed in the injection path connected to the solution inlet port of the storage container.
  • a solution such as a cell suspension, a diluent, a priming solution in the storage container.
  • the process can be performed by setting the driving time of the pump.
  • This bubble sensor can be installed anywhere in the injection path, but it is more advantageous to install the bubble sensor as close to the storage container as possible to reduce the amount of liquid remaining in the injection path.
  • another bubble sensor may be provided on the upper part of the storage container. By installing this bubble sensor, it is possible to determine the presence or absence of a solution near the top in the storage container. That is, when a liquid exceeding the capacity of the storage container is supplied, the sensor can detect and notify the user as an alarm.
  • the pump and the bubble sensor used in the cell suspension treatment system of the present invention those generally used can be used. It is also possible to switch the flow path by providing a clamp at a desired position in the circuit.
  • These pumps, bubble sensors, and clamps are not particularly limited, and for example, those used in dialysis machines and the like may be used.
  • the detection means detects that the cell concentrate has been concentrated to a predetermined volume, and the cell concentrate is sent from the storage container to the cell suspension processor.
  • the concentration is terminated by the control means for stopping.
  • the cell suspension depends on the cell suspension concentration, cell size, cell type, etc. Because the degree of concentration in the processor is not constant, and concentration may occur until air enters the cell suspension processor, the concentration of the cell suspension It was necessary to monitor the condition, and automation was difficult.
  • the end of the cell suspension concentration step is determined using the detection means, so that the inside of the cell suspension treatment device can be used regardless of the state of the cell suspension. Thus, it is possible to obtain a sufficiently concentrated cell concentrate with high accuracy without air entering.
  • FIG. 1 is a circuit diagram of a system having a detecting means for detecting the amount of a cell concentrate in a communication pipe for introducing a circulation circuit, which is an embodiment of a cell suspension treatment system A used in the present invention. Show.
  • the cell suspension processing system A in FIG. 1 has an injection path 27 having a branched tip.
  • Each branched end portion is a cell culture bag connection portion 1 and a diluent bag connection portion 2.
  • Clamps 22 and 21 are provided in the injection path 27 on the storage container 3 side from the cell culture bag connection part 1 and the diluent bag connection part 2, respectively, and the cell culture bag connection part 1 is opened and closed by opening and closing the clamps 22 and 21.
  • the solution supplied from the diluent bag connecting portion 2 to the storage container 3 can be switched.
  • the pump 12 is provided in the injection path 27 on the storage container 3 side from the branch portion, and the supply amount of the solution to the storage container 3 can be adjusted by adjusting the driving speed.
  • a bubble sensor 10 is installed in the injection path 27 on the storage container 3 side from the pump 12. If the bubble sensor 10 detects the air that has entered the injection path 27 after the solution being supplied disappears, the supply of the solution to the storage container 3 can be stopped at an optimal timing by stopping the pump 12. . Further, by electrically connecting the pump 12 and the bubble sensor 10, supply of the solution can be automatically adjusted. The other end of the injection path 27 is connected to the solution inlet port 15 at the lower part of the storage container 3.
  • a circulation outlet port 16 and a circulation inlet port 17 are arranged at the lower part of the storage container 3, so that the interior of the storage container 3 is at atmospheric pressure above the storage container 3.
  • An air filter 8 is provided.
  • a bubble sensor 9 is installed in the path from the storage container 3 to the air filter 8 so that it can be detected that a solution having a volume equal to or larger than the volume of the storage container 3 is supplied.
  • the bubble sensor 9 can be automatically connected to the pump 12 to automatically stop the supply of the solution.
  • the circulation inlet port 17 is connected to the cell suspension introduction port 18 at the upper part of the cell suspension treatment device 6 through the introduction communication pipe 28.
  • a bubble sensor 11 is installed in the introduction communication pipe 28, and a pump 13 is installed on the cell suspension treatment device 6 side from the bubble sensor 11.
  • the solution in the storage container 3 can be supplied to the cell suspension treatment device 6.
  • the bubble sensor 11 detects the air that has entered the introduction communication pipe 28, the cell is stopped by stopping the pump 13.
  • the supply of the solution can be stopped at an optimal timing without introducing air into the suspension treatment device 6. Further, by electrically connecting the pump 13 and the bubble sensor 11, the supply of the solution can be automatically adjusted.
  • the cell suspension treatment device 6 is filled with a hollow fiber separation membrane (not shown).
  • a hollow fiber separation membrane (not shown).
  • the liquid is separated.
  • the separated liquid is discharged from the filtrate outlet 20 provided on the upper side surface of the cell suspension treatment device 6.
  • the filtrate outlet 20 is connected to the waste liquid container 4 via a pipe, and this pipe is provided with a pump 14 for promoting the discharge of the filtrate and the concentration in the hollow fiber separation membrane.
  • the cell suspension outlet 19 at the lower part of the cell suspension treatment device 6 is connected to the circulation outlet port 16 via a communication pipe 29 for derivation.
  • the outlet communication pipe 29 is provided with a clamp 23. By opening and closing the clamp 23, the circulation of the cell concentrate concentrated by the cell suspension treatment device 6 to the storage container 3 can be adjusted. it can.
  • the introduction communication pipe 28 and the lead-out communication pipe 29 serve as a circulation circuit 30 that circulates a cell suspension and a cell concentrate between the storage container 3 and the cell suspension treatment device 6.
  • a branching portion is provided in the lead-out communication pipe 29 on the cell suspension treatment device 6 side of the clamp 23, and the branching portion and the collection container 5 are connected via a collection path 31.
  • a clamp 24 is provided in the recovery path 31. The clamp 24 is closed during the circulation / concentration using the circulation circuit 30 as described above. When collecting the cell concentrate, the cell concentrate can be supplied to the collection container 5 by opening the clamp 24.
  • FIG. 2 is a circuit diagram of a system having a detection means for detecting the amount of the cell concentrate in the storage container, which is another embodiment of the cell suspension treatment system A ′ used in the present invention. Show.
  • the injection path 27 has a priming solution bag connection portion 26 in addition to the cell culture bag connection portion 1 and the diluent bag connection portion 2.
  • the priming liquid bag connection portion 26 is the other end of the branch portion provided in the injection path 27 on the storage container 3 side from the diluent bag connection portion 2.
  • a clamp 25 is provided between the priming liquid bag connection part 26 and the branch part, and the supply of the priming liquid to the storage container 3 can be adjusted by opening and closing the clamp 25.
  • another branch portion is provided on the side of the storage container 3 from the bubble sensor 10 provided in the injection path 27, and a circuit 32 that communicates the branch portion with the upper portion of the storage container 3 is provided, so that the solution Is filled in the storage container 3, the liquid level in the storage container 3 and the liquid level of the solution in the circuit 32 are parallel through the injection path 27. Then, by installing the bubble sensor 9a at a desired height of the circuit 32, when the bubble sensor is directly provided in the storage container 3, the circuit 32 is compared with the case where a bubble sensor having a large detection range is required. The liquid level of the solution in the storage container 3 can be detected even with a compact bubble sensor that can narrow the range for detecting the liquid level inside.
  • the concentration when the concentration is performed, a cell suspension or the like is circulated between the storage container 3 and the cell suspension treatment device 6 by the pump 13 installed in the communication pipe for introduction 28.
  • the introduction communication pipe 28 Is connected to the introduction communication pipe 28, it is difficult to accurately measure the liquid level even with the bubble sensor 9a on the circuit 32 due to the pulsation of the pump 13.
  • the circuit 32 is connected to the injection path 27, which is a different path from the introduction communication pipe 28, so that the liquid level of the circuit 32 can be accurately set as the liquid level of the liquid in the storage container 3.
  • variation of a liquid level can be suppressed by using the thing with a thin aperture, but there is no limitation in particular about an aperture.
  • the chamber 7 may be provided at a position higher than the bubble sensor 9a. By providing this chamber 7, there is an advantage that the fluctuation of the liquid level can be suppressed as compared with the case of the circuit 32 alone.
  • the circuit 32 may be provided with a branch portion at a position higher than the upper portion of the storage container 3, and the air filter 8 may be provided at a position higher than the branch portion as in FIG. Further, another bubble sensor 9 b may be provided between the branch portion and the air filter 8. With this configuration, even when a cell suspension exceeding the volume of the storage container 3 is supplied, the cell suspension leaks from the air filter 8 when the bubble sensor 9b is activated and the pump 12 is stopped. Can be suppressed.
  • the bubble sensor 9b can perform automatic processing by being electrically connected to the pump 12.
  • the recovery path 31 may be in a mode such as a cell suspension processing system A ′′ shown in FIG. That is, a collection port 33 may be provided in the storage container 3 and a collection path 31 ′ in which the collection port 33 and the collection container 5 are connected may be used. A clamp 34 may be provided in this path.
  • the cell suspension treatment device 6 may be provided with a cell concentrate recovery port 35, and the cell concentrate recovery port 35 and the recovery container 5 may be connected to form a recovery path 31 ''.
  • a clamp 36 may be provided in this path.
  • the method for producing a cell concentrate of the present invention uses a cell suspension treatment system having the above-described configuration, a) supplying and storing a cell suspension from the solution inlet port to a storage container; b) The cell suspension in the storage container is passed through the circulation circuit introduction communication pipe to the cell suspension processor, and then circulated to the storage container through the circulation circuit lead-out communication pipe. Concentrating the suspension; c) a step of stopping the step b) by detecting the amount of the cell concentrate in the storage container or the communication pipe for introduction of the circulation circuit; d) a step of feeding the cell concentrate in the storage container, the cell suspension treatment device, and the circulation circuit to the recovery container through a recovery path and recovering it.
  • each clamp shall be previously closed before manufacture.
  • the amount of liquid to be stored can be stored without any limitation unless it exceeds the capacity of the storage container.
  • the flow rate is preferably in the range of 50 mL / min to 300 mL / min.
  • the storage step and the concentration step may be repeated until the amount of liquid in the cell suspension bag connected to the cell culture bag connection portion 1 reaches a predetermined amount, or the storage step and the concentration step are performed simultaneously in parallel. May be.
  • the cell suspension in the cell suspension bag may be processed up to a certain amount using the driving time of the pump 12 or the like.
  • the liquid feeding by the pump 12 may be controlled by detecting bubbles flowing in using the bubble sensor 10.
  • priming may be performed before the step a).
  • the clamp 21 is opened, the clamp 22 is closed, and physiological saline is stored in the storage container 3 as a priming solution from the diluent bag connecting portion 2.
  • the pump 12 is driven and stored in the storage container 3 at a predetermined flow rate.
  • the amount of liquid to be stored is not particularly limited as long as the amount of liquid that the circulation circuit 30 and the cell suspension treatment device 6 are immersed in physiological saline is stored.
  • the flow rate is preferably in the range of 50 mL / min to 300 mL / min.
  • the pump 13 installed in the communication pipe 28 for introduction of the circulation circuit 30 in which the clamp 23 is opened, the clamp 24 is confirmed to be closed, and the storage container 3 and the cell suspension treatment device 6 are connected;
  • route connected to the outlet 20 for filtration is driven, and the priming in the circulation circuit 30 and the cell suspension processing device 6 is performed.
  • the pump 14 After filling the inside of the circulation circuit 30 with the priming liquid at a predetermined flow rate by the pump 13, the pump 14 is driven to filter the priming liquid outside the hollow fiber separation membrane, and the inside 6 of the cell suspension processor is filled with the priming liquid. Fulfill.
  • the circulation direction can be circulated without any restriction in either the forward direction or the reverse direction.
  • the pump 14 can be set without particular limitation as long as it is lower than the flow rate of the pump 13. In addition, when the flow rate of the pump 14 is higher than the flow rate of the pump 13, there is a concern that the circulation circuit 30 may not be filled with liquid, which is not preferable.
  • the flow rate of the pump 13 is preferably adjusted in the range of 50 mL / min to 500 mL / min.
  • the clamp 21 is opened, the clamp 22 is closed, and the diluent is fed into the storage container 3 by the pump 12 to store the cell suspension.
  • the cell suspension in the container 3 may be diluted (dilution step). After diluting unnecessary components in the cell suspension in this dilution step, concentration is again performed in step b), and then the concentration is stopped in step c), whereby unnecessary components in the cell suspension are hollowed out. It is possible to produce a cell concentrate from which unnecessary components are further removed by filtration and removal with a thread membrane. In addition, you may repeat this dilution process 2 times or more as needed.
  • the pump 13 is driven in the reverse direction so that the liquid level of the cell concentrate is the circulation inlet port below the storage container 3.
  • the pump 13 is driven in the reverse direction so that the liquid level of the cell concentrate is the circulation inlet port below the storage container 3.
  • the bag containing the priming solution and the bag containing the diluting solution may be replaced.
  • the storage step of the a) step and the concentration step of the b) step may be performed in parallel.
  • the processing time can be shortened by performing the step a) and the step b) in parallel.
  • the specific example which manufactures the cell concentrate at the time of using cell concentration processing system A 'shown in FIG. 2 is described below.
  • the storage process of a) process can be processed similarly to the case where the cell concentration processing system A shown in FIG. 1 is used.
  • the priming solution bag is connected to the priming solution bag connecting portion 26 and the clamps 21 and 25 are opened.
  • the plumbing liquid may be stored in the storage container 3.
  • the diluent bag may be attached to the diluent bag connecting portion 2.
  • the concentration step of the step is sufficiently advanced, and the amount of the cell concentrate in the storage container 3 is detected by the bubble sensor 9a provided in the circuit 32, so that the pumps 13 and 14 are stopped and the concentration is performed. Stop (step c)). Thereafter, the cell suspension may be further added to the storage container 3, or a dilution step with a diluent may be performed as described above. In this case, the steps b) and c) may be performed again.
  • the recovery step d) is performed in the same manner as in the case of using the cell concentration treatment system A shown in FIG.
  • Examples of cells that can be concentrated according to the present invention include artificial pluripotent stem cells (iPS cells), embryonic stem cells (ES cells), mesenchymal stem cells, adipose-derived mesenchymal cells, adipose-derived stromal stem cells, pluripotency Multipotent biological stem cells such as adult stem cells, bone marrow stromal cells, hematopoietic stem cells, lymphocytes such as T cells, B cells, killer T cells (cytotoxic T cells), NK cells, NKT cells, regulatory T cells Cells, macrophages, monocytes, dendritic cells, granulocytes, erythrocytes, platelets, neurons, somatic cells such as myocytes, fibroblasts, hepatocytes, cardiomyocytes, or treatments such as gene transfer or differentiation The cell which performed is illustrated.
  • iPS cells artificial pluripotent stem cells
  • ES cells embryonic stem cells
  • mesenchymal stem cells adipose-derived mesen
  • the cell suspension used in the present invention is not particularly limited as long as it is a suspension containing the cells.
  • fat, skin, blood vessel, cornea, oral cavity, kidney, liver, pancreas, heart, nerve, Suspensions, blood, and bone marrow fluids that have been subjected to enzyme treatment, crushing treatment, extraction treatment, degradation treatment, ultrasonic treatment, etc.
  • biological tissues such as muscle, prostate, intestine, amniotic membrane, placenta, and umbilical cord
  • biological tissues such as muscle, prostate, intestine, amniotic membrane, placenta, and umbilical cord
  • cell suspensions prepared by pretreatment such as filtration treatment, enzyme treatment, decomposition treatment, and ultrasonic treatment.
  • a culture solution such as DMEM, ⁇ -MEM, MEM, IMEM, RPMI-1640, or stimulating factors such as cytokines, antibodies, peptides, etc.
  • stimulating factors such as cytokines, antibodies, peptides, etc.
  • a turbid liquid is illustrated.
  • Example 1 The cell suspension was concentrated using the cell suspension treatment system A shown in FIG. The clamps 21, 22, 23, and 24 were all closed. In addition, the cell suspension used was obtained by culturing jurkat cells in RPMI-1640 medium containing 10% FBS.
  • the bag containing the cell suspension was connected to the cell culture bag connection 1 and the physiological saline bag was connected to the diluent bag connection 2.
  • the clamp 21 was opened, it was confirmed that the clamp 22 was closed, the pump 12 was set to a flow rate of 300 mL / min and was driven for 60 seconds, and physiological saline was stored in the storage container 3.
  • the clamp 23 is opened, it is confirmed that the clamp 24 is closed, the pump 13 is set to 450 mL / min, the pump 14 is set to 150 mL / min, and the pump 23 is driven. Priming in 6 was performed. At this time, the driving direction of the pump 13 was set to a direction in which the priming solution flows from the top to the bottom in the cell suspension treatment device 6. When the bubble sensor 11 detected bubbles, the pump 13 and the pump 14 were stopped. In order to prevent bubbles from entering the cell suspension treatment device 6, the pump 13 was driven in the reverse direction to return the physiological saline liquid level to the vicinity of the circulation inlet port 17 at the bottom of the storage container 3. .
  • the flow rates were set so that the pump 12 was 200 mL / min, the pump 13 was 450 mL / min, and the pump 14 was 200 mL / min, and concentrated while circulating in the circulation circuit 30 with the cell suspension. .
  • the liquid flow direction in the circulation circuit 30 was set to the direction of flowing from the circulation inlet port 17 of the storage container 3 to the cell suspension introduction port 18 of the cell suspension treatment device 6 (step (b)).
  • the pump 12 was stopped. Subsequently, the pump 13 and the pump 14 were driven to concentrate the cell suspension in the storage container 3, and after the bubble sensor 11 detected the bubbles, the pump 13 and the pump 14 were stopped (step (c)). In order to prevent bubbles from entering the cell suspension treatment device 6, the pump 13 is driven in the reverse direction so that the liquid level of the cell suspension is returned to the vicinity of the circulation inlet port 17 at the bottom of the storage container 3. It was.
  • the clamp 21 is opened, the clamp 22 is closed, the pump 12 is driven at 200 mL / min, and the pump 13 is driven at 450 mL / min for 120 seconds, and physiological saline is added to the storage container 3.
  • the cell suspension was diluted with Subsequently, the respective flow rates were set so that the pump 13 was 450 mL / min and the pump 14 was 200 mL / min, and the cell suspension was filtered and concentrated again. Note that the pump 13 and the pump 14 were stopped after the bubble sensor 11 detected the bubbles.
  • the recovered cell suspension is a cell concentrate in which unnecessary components in the cell suspension are reduced to a target concentration, and in the priming, concentration (b), and concentration stop (c) steps, Since there was no air intrusion into the suspension treatment device 6, there was little loss of cells and concentration was possible with high precision.
  • the cell viability ratio obtained by dividing the cell viability after the treatment by the cell viability before the treatment was 99% or more, and no cell damage was observed. The cell viability was measured by a known method.
  • Comparative Examples 1 and 2 The processing of the cell suspension carried out using the cell suspension processing system B outlined in FIG. 4 will be described.
  • the cell suspension processing system B shown in FIG. 4 has the same configuration as the cell suspension processing system A shown in FIG. 1 except that the bubble sensor 11 is not installed in the introduction communication pipe 28 of the circulation circuit 30. .
  • Comparative Example 1 and Comparative Example 2 cell suspensions prepared under the same conditions as in Example 1 were used, but different cell culture bags were used.
  • the bag containing the cell suspension was connected to the cell culture bag connection 1 and the physiological saline bag was connected to the diluent bag connection 2.
  • the clamp 21 was opened, the clamp 22 was closed, the pump 12 was set to have a flow rate of 300 mL / min, and the physiological saline was stored in the storage container 3 by driving for 60 seconds.
  • the clamp 23 is opened, it is confirmed that the clamp 24 is closed, the pump 13 is set to 450 mL / min, the pump 14 is set to a flow rate of 150 mL / min, and the circulation circuit 30 and the cell suspension treatment device 6 are set. Inside priming was done. At this time, the driving direction of the pump 13 was set to a direction in which the priming solution flows from the top to the bottom in the cell suspension treatment device 6. After the pumps 13 and 14 were driven for 100 seconds, the pumps 13 and 14 were stopped.
  • the clamp 22 is opened, the clamp 21 is closed, the pump 12 is set at a flow rate of 300 mL / min from the cell culture bag connection 1, and is driven for 60 seconds to store the cell suspension in the storage container 3 ( a) Step).
  • the pump 12 is driven at 200 mL / min
  • the pump 13 is set at 450 mL / min
  • the pump 14 is driven at 200 mL / min to drive between the reservoir 3 and the cell suspension treatment device 6.
  • the solution was concentrated while being circulated in the cell suspension through the circulation circuit 30.
  • the liquid flow direction in the circulation circuit 30 was set to the direction of flowing from the circulation inlet port 17 of the storage container 3 to the cell suspension introduction port 18 of the cell suspension treatment device 6 (step (b)).
  • the pump 12 was stopped after the bubble sensor 10 detected the bubbles. Subsequently, the pump 13 and the pump 14 were driven to concentrate the cell suspension in the storage container 3, and after the pump 14 was driven for 70 seconds, the pump 13 and the pump 14 were stopped (step (c)).
  • the driving time of 70 seconds for the pump 14 was a time when it was expected that ideal concentration could be performed in consideration of the flow rates of the pumps 12, 13, and 14.
  • the clamp 21 is opened, the clamp 22 is closed, the flow rate is adjusted so that the pump 12 is 200 mL / min and the pump 13 is 450 mL / min, and the pump is driven for 120 seconds.
  • the cell suspension in the storage container 3 was diluted.
  • the flow rate was set so that the pump 13 was 450 mL / min and the pump 14 was 200 mL / min, and the cell suspension was filtered.
  • the pump 12 was driven for 120 seconds and then stopped.
  • the clamp 24 is opened, the clamp 23 is closed, the pump 13 is turned on at 100 mL / min, and the cell suspension is supplied from the circulation inlet port 17 of the storage container 3 to the cell suspension inlet 18 of the cell suspension processor 6.
  • the cell suspension in the cell suspension treatment device 6 and the circulation circuit 30 was collected from the collection path 31 to the collection container 5 (step (d)).
  • Comparative Example 2 performed by the same processing method, the cause is unknown, but since the amount of liquid filtered by the pump 14 was small as opposed to Comparative Example 1, before moving to the step of diluting with physiological saline. The amount of liquid in the storage container 3 increased, and the amount of unnecessary components in the cell concentrate could not be reduced to the target concentration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Sustainable Development (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Computer Hardware Design (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
PCT/JP2014/068936 2013-07-23 2014-07-16 細胞濃縮液の製造方法および細胞懸濁液処理システム WO2015012174A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US14/906,320 US10113144B2 (en) 2013-07-23 2014-07-16 Method for producing cell concentrate, and cell suspension treatment system
CN201480041539.XA CN105408467A (zh) 2013-07-23 2014-07-16 细胞浓缩液的制造方法以及细胞悬浊液处理系统
EP14829330.1A EP3026107B1 (de) 2013-07-23 2014-07-16 Verfahren zur herstellung eines zellkonzentrats und zellensuspensionsbehandlungssystem
US16/142,857 US10533151B2 (en) 2013-07-23 2018-09-26 Method for producing cell concentrate, and cell suspension treatment system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013152755 2013-07-23
JP2013-152755 2013-07-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/906,320 A-371-Of-International US10113144B2 (en) 2013-07-23 2014-07-16 Method for producing cell concentrate, and cell suspension treatment system
US16/142,857 Division US10533151B2 (en) 2013-07-23 2018-09-26 Method for producing cell concentrate, and cell suspension treatment system

Publications (1)

Publication Number Publication Date
WO2015012174A1 true WO2015012174A1 (ja) 2015-01-29

Family

ID=52393217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/068936 WO2015012174A1 (ja) 2013-07-23 2014-07-16 細胞濃縮液の製造方法および細胞懸濁液処理システム

Country Status (5)

Country Link
US (2) US10113144B2 (de)
EP (1) EP3026107B1 (de)
JP (1) JP6384166B2 (de)
CN (1) CN105408467A (de)
WO (1) WO2015012174A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016190069A1 (ja) * 2015-05-28 2016-12-01 株式会社日立製作所 液体還流容器、細胞濃縮装置及び細胞濃縮システム
WO2016190313A1 (ja) * 2015-05-25 2016-12-01 ニプロ株式会社 濃縮装置及び細胞懸濁液の濃縮方法
EP4108307A2 (de) 2021-06-24 2022-12-28 Yokogawa Electric Corporation Vorrichtung zum verarbeiten von flüssigkeiten in zellkulturverfahren

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016190312A1 (ja) * 2015-05-25 2016-12-01 ニプロ株式会社 培養装置
JP6677248B2 (ja) * 2015-05-25 2020-04-08 ニプロ株式会社 培養装置
CA2988321A1 (en) * 2015-06-04 2016-12-08 Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico System of multiple bags and method for the preparation of hemocomponents
JP6930068B2 (ja) * 2016-03-30 2021-09-01 東洋紡株式会社 中空糸モジュールを用いる細胞培養方法
CN105925475B (zh) * 2016-06-16 2018-02-09 芜湖中科医凌生命科技有限公司 一种全自动浓缩处理仪
EP3299049B1 (de) * 2016-09-21 2022-11-02 Fenwal, Inc. System zur aufrechterhaltung der patientenflüssigkeitsbilanz während einer extrakorporalen therapeutischen zellbehandlung
JP6989907B2 (ja) * 2016-09-27 2022-02-15 吉和 米満 懸濁液を無菌的に処理するための器具
WO2018129467A1 (en) * 2017-01-08 2018-07-12 Cesca Therapeutics, Inc. Devices and methods for bio-processing cellular samples
WO2018212354A1 (ja) * 2017-05-19 2018-11-22 国立大学法人徳島大学 原液処理装置および原液処理装置の操作方法
WO2019059279A1 (ja) * 2017-09-20 2019-03-28 株式会社カネカ 細胞懸濁液を調製するためのデバイス、システム及び方法
ES2985973T3 (es) * 2017-12-28 2024-11-08 I Sep Sistema y procedimiento de tratamiento del líquido hemorrágico para autotransfusión
CN108441407B (zh) * 2018-04-02 2022-05-13 天晴干细胞股份有限公司 一种细胞自动纯化冻存装置
US20210261907A1 (en) * 2018-05-13 2021-08-26 Gpb Scientific, Inc. Combined Purification and Concentration by Deterministic Lateral Displacement With Recirculation of Product
CA3109705A1 (en) * 2018-10-02 2020-04-09 The Doshisha Method and vessel for preserving corneal endothelial cells
KR20210143790A (ko) 2019-03-26 2021-11-29 가부시키가이샤 메가카리온 세포 현탁액 처리 장치
FR3097770B1 (fr) 2019-06-27 2024-03-01 I Sep Système et procédé de traitement de liquide hémorragique pour de l’autotransfusion
EP4183432A4 (de) * 2020-08-19 2024-11-06 Shanghai Xinguang Bio-Pharmaceutical Ltd. Fluidbehandlungsverfahren und fluidbehandlungsvorrichtung
CN116672533A (zh) 2020-08-19 2023-09-01 上海心光生物医药有限责任公司 医疗设备
CN112844048A (zh) * 2021-03-02 2021-05-28 河南大学 一种用于微藻的气压式膜浓缩系统及浓缩方法
WO2022266343A1 (en) * 2021-06-16 2022-12-22 The Methodist Hospital System Closed-loop adipose transplant systems and kits, controllers, and methods related thereto
CN115970491B (zh) * 2021-10-14 2025-01-14 厦门大学 超滤系统

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3012689B2 (ja) 1990-03-07 2000-02-28 旭メディカル株式会社 自己血液の回収膜システム及び方法
JP2007524396A (ja) 2003-06-25 2007-08-30 サイトリ セラピューティクス インコーポレイテッド 組織から再生細胞を分離して濃縮するためのシステム及び方法
JP4307714B2 (ja) 1998-01-08 2009-08-05 ネクセル セラピューティックス インコーポレイティド 血球を再循環洗浄するのに用いる方法、バッグおよび使い捨てセット
JP2012120456A (ja) * 2010-12-06 2012-06-28 Kaneka Corp プライミング時の気泡の除去を簡便にする部材を備えた細胞溶液処理器具およびその使用方法
JP2012210187A (ja) * 2011-03-31 2012-11-01 Kaneka Corp 細胞懸濁液の濃縮方法
WO2013061859A1 (ja) * 2011-10-24 2013-05-02 株式会社カネカ 細胞濃縮液の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4964976A (en) * 1989-04-04 1990-10-23 Lysaght Michael J Optimized filter and method
US6302860B1 (en) * 1999-02-17 2001-10-16 Medtronic, Inc. Venous filter for assisted venous return
JP4457235B2 (ja) * 2001-12-18 2010-04-28 株式会社北九州バイオフィジックス研究所 自動血液透析装置および該装置を使用したプライミング方法。
US7201870B2 (en) * 2003-01-14 2007-04-10 Medtronic, Inc. Active air removal system operating modes of an extracorporeal blood circuit
US7204958B2 (en) * 2003-01-14 2007-04-17 Medtronic, Inc. Extracorporeal blood circuit air removal system and method
US7335334B2 (en) * 2003-01-14 2008-02-26 Medtronic, Inc. Active air removal from an extracorporeal blood circuit
CN2601095Y (zh) * 2003-02-25 2004-01-28 中国人民解放军军事医学科学院野战输血研究所 血细胞透析洗涤机
JP4861649B2 (ja) * 2005-07-08 2012-01-25 テルモ株式会社 血液成分採取回路および血液成分採取装置
WO2008125893A1 (en) * 2007-04-12 2008-10-23 Gambro Lundia Ab Method and apparatus for priming an extracorporeal blood circuit.
US20110223583A1 (en) * 2008-11-24 2011-09-15 Early Warning Inc. Devices and methods for providing concentrated biomolecule condensates to biosensing devices
US8512566B2 (en) * 2009-12-11 2013-08-20 General Electric Company Disposable fluid path systems and methods for processing complex biological materials

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3012689B2 (ja) 1990-03-07 2000-02-28 旭メディカル株式会社 自己血液の回収膜システム及び方法
JP4307714B2 (ja) 1998-01-08 2009-08-05 ネクセル セラピューティックス インコーポレイティド 血球を再循環洗浄するのに用いる方法、バッグおよび使い捨てセット
JP2007524396A (ja) 2003-06-25 2007-08-30 サイトリ セラピューティクス インコーポレイテッド 組織から再生細胞を分離して濃縮するためのシステム及び方法
JP2012120456A (ja) * 2010-12-06 2012-06-28 Kaneka Corp プライミング時の気泡の除去を簡便にする部材を備えた細胞溶液処理器具およびその使用方法
JP2012210187A (ja) * 2011-03-31 2012-11-01 Kaneka Corp 細胞懸濁液の濃縮方法
WO2013061859A1 (ja) * 2011-10-24 2013-05-02 株式会社カネカ 細胞濃縮液の製造方法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016190313A1 (ja) * 2015-05-25 2016-12-01 ニプロ株式会社 濃縮装置及び細胞懸濁液の濃縮方法
JPWO2016190313A1 (ja) * 2015-05-25 2018-03-15 ニプロ株式会社 濃縮装置及び細胞懸濁液の濃縮方法
US10793822B2 (en) 2015-05-25 2020-10-06 Nipro Corporation Concentrating device and method for concentrating cell suspension
WO2016190069A1 (ja) * 2015-05-28 2016-12-01 株式会社日立製作所 液体還流容器、細胞濃縮装置及び細胞濃縮システム
CN107532122A (zh) * 2015-05-28 2018-01-02 株式会社日立制作所 液体回流容器、细胞浓缩装置和细胞浓缩系统
EP4108307A2 (de) 2021-06-24 2022-12-28 Yokogawa Electric Corporation Vorrichtung zum verarbeiten von flüssigkeiten in zellkulturverfahren

Also Published As

Publication number Publication date
JP2015042167A (ja) 2015-03-05
JP6384166B2 (ja) 2018-09-05
US20160168529A1 (en) 2016-06-16
CN105408467A (zh) 2016-03-16
EP3026107B1 (de) 2020-04-08
US10533151B2 (en) 2020-01-14
EP3026107A1 (de) 2016-06-01
EP3026107A4 (de) 2017-03-15
US20190024037A1 (en) 2019-01-24
US10113144B2 (en) 2018-10-30

Similar Documents

Publication Publication Date Title
JP6384166B2 (ja) 細胞濃縮液の製造方法および細胞懸濁液処理システム
US11555174B2 (en) Method for proliferation of cells within a bioreactor using a disposable pumphead and filter assembly
US9603356B2 (en) Method for producing cell concentrate
JP6528399B2 (ja) 細胞濃縮液の製造方法
JP6196222B2 (ja) 細胞濃縮液の製造方法
US20080171951A1 (en) Integrated System for Collecting, Processing and Transplanting Cell Subsets, Including Adult Stem Cells, for Regenerative Medicine
JP6685231B2 (ja) 中空糸膜モジュールのプライミング方法
JP7300486B2 (ja) 衝撃波または機械的衝撃を使用する、細胞の分離、解離、および／または脱凝集
CN107532122A (zh) 液体回流容器、细胞浓缩装置和细胞浓缩系统
US20170218330A1 (en) Systems and methods for the separation of cells from microcarriers using a spinning membrane
TWI741033B (zh) 用以無菌處理懸濁液之器具、細胞製備用套組及細胞之製備方法
JP2012210187A (ja) 細胞懸濁液の濃縮方法
JP2015012837A (ja) 細胞濃縮液の製造方法
JP2003507149A (ja) 循環流体を生物学的に処理するための神経膠星状細胞装置
JP6285649B2 (ja) 細胞濃縮液の製造方法
JP7212509B2 (ja) 細胞濃縮方法
JP2019092393A (ja) 細胞懸濁液調製用容器および細胞懸濁液の調製方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480041539.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14829330

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14906320

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2014829330

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE